Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

Patient, treatment and discharge factors associated with hospital readmission within 30 days after surgical cytoreduction for epithelial ovarian carcinoma.

Clark RM, Growdon WB, Wiechert A, Boruta D, Del Carmen M, Goodman AK, Bradford L, Rauh-Hain A, Schorge JO.

Gynecol Oncol. 2013 Sep;130(3):407-10. doi: 10.1016/j.ygyno.2013.05.034. Epub 2013 Jun 5.

PMID:
23747329
2.

Assessment of risk factors for 30-day hospital readmission after surgical cytoreduction in epithelial ovarian carcinoma.

Fauci JM, Schneider KE, Frederick PJ, Wilding G, Consiglio J, Sutton AL, Kilgore LC, Barnes MN.

Int J Gynecol Cancer. 2011 Jul;21(5):806-10. doi: 10.1097/IGC.0b013e3182157a19.

PMID:
21412162
3.

Optimal primary surgical treatment for advanced epithelial ovarian cancer.

Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R.

Cochrane Database Syst Rev. 2011 Aug 10;(8):CD007565. doi: 10.1002/14651858.CD007565.pub2. Review.

PMID:
21833960
4.

Risk factors and indications for 30-day readmission after primary surgery for epithelial ovarian cancer.

AlHilli M, Langstraat C, Tran C, Martin J, Weaver A, McGree M, Mariani A, Cliby W, Bakkum-Gamez J.

Int J Gynecol Cancer. 2015 Feb;25(2):193-202. doi: 10.1097/IGC.0000000000000339.

5.

Intraoperative hypothermia during primary surgical cytoreduction for advanced ovarian cancer: risk factors and associations with postoperative morbidity.

Long KC, Tanner EJ, Frey M, Leitao MM Jr, Levine DA, Gardner GJ, Sonoda Y, Abu-Rustum NR, Barakat RR, Chi DS.

Gynecol Oncol. 2013 Dec;131(3):525-30. doi: 10.1016/j.ygyno.2013.08.034. Epub 2013 Sep 7.

PMID:
24016410
6.

Patient, treatment and discharge factors associated with hospital readmission within 30days after surgery for vulvar cancer.

Dorney KM, Growdon WB, Clemmer J, Rauh-Hain JA, Hall TR, Diver E, Boruta D, Del Carmen MG, Goodman A, Schorge JO, Horowitz N, Clark RM.

Gynecol Oncol. 2017 Jan;144(1):136-139. doi: 10.1016/j.ygyno.2016.11.009. Epub 2016 Nov 8.

PMID:
27836203
7.

Perioperative morbidity and mortality in octogenarians with ovarian cancer.

Walters CL, Schneider KE, Whitworth JM, Fauci JM, Smith HJ, Barnes MN, Straughn JM.

Int J Gynecol Cancer. 2013 Jul;23(6):1006-9. doi: 10.1097/IGC.0b013e3182980fac.

PMID:
23714708
8.

Risk factors associated with readmission after pediatric cardiothoracic surgery.

Kogon B, Jain A, Oster M, Woodall K, Kanter K, Kirshbom P.

Ann Thorac Surg. 2012 Sep;94(3):865-73. doi: 10.1016/j.athoracsur.2012.04.025. Epub 2012 Jun 8.

PMID:
22682942
9.
10.

Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: a Gynecologic Oncology Group study.

Rungruang B, Miller A, Richard SD, Hamilton CA, Rodriguez N, Bookman MA, Maxwell GL, Krivak TC, Horowitz NS.

Gynecol Oncol. 2012 Jan;124(1):53-8. doi: 10.1016/j.ygyno.2011.09.024. Epub 2011 Oct 26.

PMID:
22032836
11.

Use of complex surgical procedures, patterns of tumor spread, and CA-125 predicts a risk of incomplete cytoreduction: a Korean Gynecologic Oncology Group study (KGOG-3022).

Jung DC, Kang S, Kim SC, Kim JW, Nam JH, Ryu SY, Seong SJ, Kim BG.

Gynecol Oncol. 2013 Nov;131(2):336-40. doi: 10.1016/j.ygyno.2013.07.110. Epub 2013 Aug 13.

PMID:
23954903
12.

The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.

Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Poynor EA, Aghajanian C, Jarnagin WR, DeMatteo RP, D'Angelica MI, Barakat RR, Chi DS.

Gynecol Oncol. 2006 Dec;103(3):1083-90. Epub 2006 Aug 4.

PMID:
16890277
13.

Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer.

Wright JD, Herzog TJ, Neugut AI, Burke WM, Lu YS, Lewin SN, Hershman DL.

Obstet Gynecol. 2012 Oct;120(4):871-81.

PMID:
22996105
14.

Unplanned 30-day hospital readmission as a quality measure in gynecologic oncology.

Wilbur MB, Mannschreck DB, Angarita AM, Matsuno RK, Tanner EJ, Stone RL, Levinson KL, Temkin SM, Makary MA, Leung CA, Deutschendorf A, Pronovost PJ, Brown A, Fader AN.

Gynecol Oncol. 2016 Dec;143(3):604-610. doi: 10.1016/j.ygyno.2016.09.020. Epub 2016 Sep 21.

PMID:
27665313
15.

Clinical characteristics associated with readmission among patients undergoing vascular surgery.

Engelbert TL, Fernandes-Taylor S, Gupta PK, Kent KC, Matsumura J.

J Vasc Surg. 2014 May;59(5):1349-55. doi: 10.1016/j.jvs.2013.10.103. Epub 2013 Dec 22.

16.

Understanding hospital readmissions after pancreaticoduodenectomy: can we prevent them?: a 10-year contemporary experience with 1,173 patients at the Massachusetts General Hospital.

Fong ZV, Ferrone CR, Thayer SP, Wargo JA, Sahora K, Seefeld KJ, Warshaw AL, Lillemoe KD, Hutter MM, Fernández-Del Castillo C.

J Gastrointest Surg. 2014 Jan;18(1):137-44; discussion 144-5. doi: 10.1007/s11605-013-2336-9. Epub 2013 Sep 4.

PMID:
24002770
17.

Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.

Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY.

Gynecol Oncol. 1999 Mar;72(3):278-87.

PMID:
10053096
18.

The surgical revolving door: risk factors for hospital readmission.

Morris DS, Rohrbach J, Rogers M, Thanka Sundaram LM, Sonnad S, Pascual J, Sarani B, Reilly P, Sims C.

J Surg Res. 2011 Oct;170(2):297-301. doi: 10.1016/j.jss.2011.04.049. Epub 2011 May 19.

PMID:
21696766
19.

Avoidable readmission in Hong Kong--system, clinician, patient or social factor?

Yam CH, Wong EL, Chan FW, Leung MC, Wong FY, Cheung AW, Yeoh EK.

BMC Health Serv Res. 2010 Nov 17;10:311. doi: 10.1186/1472-6963-10-311.

20.

Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Winter WE 3rd, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F, McGuire WP; Gynecologic Oncology Group.

J Clin Oncol. 2008 Jan 1;26(1):83-9. Epub 2007 Nov 19.

PMID:
18025437

Supplemental Content

Support Center